Many challenges and opportunities present themselves for improving the care and outcome of patients with ovarian cancer. Open, ongoing discussion between regulatory, National Cancer Institute, academic, and pharmaceutical investigators and scientists will lead to benefit and an enhanced understanding of ovarian cancer. See also pages 000-000
http://ift.tt/2qbLZUc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου